A review of the therapeutic uses of thrombin

Summary

Thrombin is the product of the hemostatic response essential to the conversion of fibrinogen to fibrin. In addition, it is also responsible for the aggregation of blood platelets in the formation of the “platelet plug” as well as the activation of factor VIII, factor V, factor XI, factor XIII and protein C. The action of thrombin is not confined to the hemostatic response as it also has a critical function in the wound healing process by stimulating ‘mitogenic’ events through interaction with cell surface receptors. In this review, we consider the various biological activities of thrombin as they relate to current therapeutic use. While there has been considerable interest in the development of fibrin sealant products, there has been considerably less interest in documenting the continuing use of thrombin as a therapeutic. The use of thrombin for topical hemostasis and the treatment of pseudoaneurysms will be discussed in detail. It is concluded that the use of thrombin as a drug will not only continue but also will significantly increase. However, the availability of a safe human thrombin preparation will be critical for the continued use of thrombin as a therapeutic.

Keywords

Pseudoaneurysms - vascular surgery - thrombin - topical hemostatic agents - interventional radiology

• References

• 1 Schmidt A. Neue Untersuchungen über die Fasterstoffgerinnung. Pflügers Arch ges. Physiol 1872; 06: 413-538.
• 2 Buchanan A. On the coagulation of the blood and other fibriniferous liquids. London Medical Gazette I 1845; New Series, p. 617. (reprinted J Physiol) 1878; 02: 158-63
• 3 Gamgee A. Some old and new experiments on the fibrin-ferment. J Physiol 1978; 02: 145-57.
• 4 Howell WH. Theories of blood coagulation. Physiol Rev 1935; 15: 435-70.
• 5 Milstone JH. On the evolution of blood clotting theory. Medicine 1952; 411-47.
• 6 Beck EA. Historical development of the prothrombin concept. in Prothrombin and Related Coagulation Factors. ed. Hempker HC, Veltkamp JJ. Leiden University Press; Leiden, The Netherlands: 1975: 15-24.
• 7 Seegers WH, Warner ED, Brinkhous KM. et al. The use of purified thrombin as a hemostatic agent. Science 1939; 89: 86.
• 8 Warner ED, Brinkhous KM, Seegers WH. et al. Further experience with the use of thrombin as a hemostatic agent. Proceedings of the Society for Experimental Biology 1939; 41: 655-57.
• 9 Tidrick RT, Seegers WH, Warner ED. Clinical Experience with Thrombin as an Hemostatic Agent. Surgery 1943; 14: 191-6.
• 10 Light RU. The antigenicity of bovine thrombin: clinical evaluation. J Neurosurg 1945; 02: 516-23.
• 11 Light RU. Hemostasis in neurosurgery. J Neurosurg 1945; 02: 414-34.
• 12 Seegers WH. Thrombin as a hemostatic agent. Prothrombin. In: Seegers WH. Harvard University Press; Cambridge, Massachusetts: 1962: 581-91.
• 13 Verstraete M. Hemostatic Drugs. In Haemostasis and Thrombosis. ed. Bloom AL, Thomas DP. Churchill Livingstone, Edinburgh; United Kingdom: 1981: 491-502.
• 14 Gamba G, Fornasari PM, Grignani G. et al. Haemostasis During Transvesical Prostatic Adenomectomy. A Controlled Trial on the Effect of Drugs with Antifibrinolytic and Thrombin-like Activities. Blut 1979; 39: 89-98.
• 15 Sanfilippo JS, Barrows GH, Yussman MA. Comparison of Avitene, Topical Thrombin, and Gelfoam as Sole Hemostatic Agent in Turboplasties. Fertility and Sterility 1980; 33: 311-6.
• 16 Vaziri ND, Robinson MA, Barton C. et al. Control of Bleeding from Cannulation Sites with Topical Thrombin in Dialyzed Patients. J Dial 1978; 02: 393-8.
• 17 Rengachary SS, Manguoglu AB. Control of bone bleeding during Cloward procedure. Technical note. J Neurosurg 1980; 52: 138-9.
• 18 Vaziri ND. (1979), Topical Thrombin and Control of Bleeding from the Fistula Puncture Sites in Dialyzed Patients. Nephron 1979; 24: 254-6.
• 19 Jasani B, Baxter-Smith DC, Donaldson LJ. et al. Topical Thrombin and Control of Wound Hematoma. Lancet 1977; II: 332-3.
• 20 Bookstein JJ, Chlosta EM, Foley D. et al. Transcatheter Hemostasis of Gastrointestinal Bleeding Using Modified Autogenous Clot. Radiology 1974; 113: 277-85.
• 21 Machovich R. Clinical use of thrombin. In The Thrombin, Volume II. ed. Machovich R. CRC Press; Boca Raton, Florida: 1984: 105-6.
• 22 Verstraete M. Hemostatic Drugs. In Haemostasis and Thrombosis. 2nd Edn. ed. Bloom AL, Thomas DP. Churchill Livingston; Edinburg, United Kingdom: 1987: 607-17.
• 23 Clark RA. Fibrin sealant in wound repair: a systematic survey of the literature. Expert Opin Investig Drugs 2000; 09: 2371-92.
• 24 Rodeo SA. Arthroscopic meniscal repair with use of the outside-in technique. Instr Course Lect 2000; 49: 195-206.
• 25 Kumar U, Albala DM. Newer techniques in intracorporeal tissue approximation: suturing, tissue adhesives, and microclips. Urol Clin North Am 2001; 28: 15-21.
• 26 Mintz PD, Mayers L, Avery N. et al. Fibrin sealant: clinical use and the development of the University of Virginia Tissue Adhesive Center. Ann Clin Lab Sci 2001; 31: 108-18.
• 27 Athanasiou KA, Shah AR, Hernandez RJ. et al. Basic science of articular cartilage repair. Clin Sports Med 2001; 20: 223-47.
• 28 Amrani DL, Diorio JP. Delmotte Y. Wound healing. Role of commercial fibrin sealants. Ann N Y Acad Sci 2001; 936: 566-79.
• 29 Drake DB, Ferguson Jr RE. Fibrin sealants in microvascular surgery: current status. J Long Term Eff Med Implants 2001; 11: 65-72.
• 30 Currie LJ, Sharpe JR, Martin R. The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. Plast Reconstr Surg 2001; 108: 1713-26.
• 31 Shekarriz B. Stoller ML. The use of fibrin sealant in urology. J Urol 2002; 167: 1218-25.
• 32 Radosevich M, Goubran HA, Burnouf T. Fibrin sealant: Scientific rationale, production methods, and current clinical use. Vox Sanguinis 1997; 72: 133-43.
• 33 Jackson MR. Fibrin sealants in surgical practice: An overview. Am J Surg 2001; 182: 1S-7S.
• 34 Kjaergard HK. Suture support: Is it advantageous?. Am J Surg 2001; 182: 15S-20S.
• 35 Reece TB, Maxey TS, Kron IL. A prospectus on tissue adhesion. Am J Surg 2001; 182: 40S-44S.
• 36 Sharma A, Kaur R, Kumar S. et al. (2003), Fibrin glue versus N-butyl-2-cyanoacrylate in corneal perforations. Ophthalmology 2003; 110: 291-8.
• 37 Maleux G, Hendrickx S, Vaninbroukx J. et al. (2003), Percutaneous injection of human thrombin to treat iatrogenic femoral pseudoaneurysms: short-and midterm ultrasound follow-up. Eur Radiol 2003; 13: 209-12.
• 38 Feld RS, Sullivan E, Morrison P. (2003), Thrombin injection for failed stent graft repair of perforated atherosclerotic aortic ulcer. J Vasc Surg 2003; 37: 194-7.
• 39 Rodeheaver GT, Hartsell L, Faulkner BC. et al. (1995), Influence of Biobrane Construction on Adherence. Journal of Burn Care and Rehabilitation 1995; 16: 321-23.
• 40 Smith DJ. Use of Biobrane in Wound Management. J Burn Care Rehabil 1995; 16: 317-20.
• 41 Shibata H, Shioya N, Kuroyanagi Y. Development of new wound dressing composed of spongy collagen sheet containing dibutyryl cyclic AMP. J Biomater Sci Polym Ed 1997; 08: 601-21.
• 42 Lorenz Ch, Petracic A, Hohl H-P. et al. Early wound closure and early reconstitution. Experience with a dermal substitute in a child with 60 per cent surface area burn. Burns 1997; 23: 505-8.
• 43 Krasner D. A Quick Reference Guide to Wound Care Product Categories. in Wound Care. A Collaborative Practice Manual for Physical Therapists and Nurses. ed. Sussman C, Bates-Jensen PM. Aspen; Gaithersburg, Md: 1998. Appendix B. 477-81.
• 44 Eggebrecht H, Haude M, Woertgen U. et al. Systematic use of a collagen-based vascular closure device immediately after cardiac catheterization procedures in 1,317 consecutive patients. Catheter Cardiovasc Interv 2002; 57: 486-95.
• 45 Paola LD, Cogo A, Deanesi W. et al. Using Hyaluronic Acid Derivatives and Cultured Autologous Fibroblasts and Keratinocytes in a Lower Limb Wound in a Patient with Diabetes: A Case Report. Ostomy Wound Manage 2002; 48: 46-9.
• 46 Guerret S, Gouignon E, Harmann DJ. et al. Long-term remodeling of a bilayered living human skin equivalent (Apigrof®) grafted onto nude mice; immunological localization of human cells and characterization of extracellular matrix. Wound Rep Regen 2003; 11: 35-45.
• 47 Kohno H, Nagasue N, Chang Y-C. et al. Comparison of Topical Hemostatic Agents in Elective Hepatic Resection: A Clinical Prospective Randomized Trial. World J Surg 1992; 16: 966-70.
• 48 Guglielmi A, Ruzzenente A, Sandri M. et al. Risk assessment and prediction of rebleeding in bleeding gastroduodenal ulcer. Endoscopy 2002; 34: 778-86.
• 49 Fletcher H, Frederick J, Hardie M. et al. A Randomized Comparison of Vasopressin and Tourniquet as Hemostatic Agents During Myomectomy. Obstet Gynecol 1996; 87: 1014-8.
• 50 Rossman JA, Rees TD. A Comparative Evaluation of Hemostatic Agents in the Management of Soft Tissue Graft Donor Site Bleeding. J Periodontol 1999; 70: 1369-75.
• 51 Halfpenny W, Fraser JS, Adlam DM. Comparison of 2 hemostatic agents for the prevention of postextraction hemorrhage in patients on anticoagulants. Oral Surg, Oral Med, Oral Pathol 2001; 92: 257-59.
• 52 Veves A, Sheehan P, Phan HT. A Randomized Controlled Trial of Promogran (A Collagen/ Oxidized Regenerated Cellulose Dressing) vs Standard Treatment in the Management of Diabetic Foot Ulcers. Arch Surg 2002; 137: 822-7.
• 53 HemCon, Inc. Portland, Oregon: http://www.hemcon.com .
• 54 Schwartz SI. Hemostasis, surgical bleeding, and transfusion. in Principles of Surgery. 4th Edn. ed. Schwartz SI, Shires GT, Spencer FC, Storer EH. McGraw-Hill; New York, New York: 1984: 100-1.
• 55 Maluf-Filho F, Sakai P, Ishioka S. et al. (2001), Endoscopic Sclerosis versus Cyanoacrylate Endoscopic Injection for the First Episode of Variceal Bleeding: A Prospective, Controlled, and Randomized Study in Child-Pugh Class C Patients. Endoscopy 2001; 33: 421-7.
• 56 Bruns TB, Worthington JM. Using tissue adhesive for wound repair: a practical guide to dermabond. Am Fam Physician 2000; 61: 1383-8.
• 57 Gosain AK. The current status of tissue glues: I. For bone fixation. Plast Reconstr Surg 2002; 109: 2581-3.
• 58 Gosain AK, Lyon VB. The current status of tissue glues: Part II. For adhesion of soft tissues. Plast Reconstr Surg 2002; 110: 1581-4.
• 59 Totaro P, Minzioni G. Patch-and-glue technique for left ventricular free wall rupture. Ann of Thorac Surg 2002; 74: 294-5.
• 60 Plow EF, Ginsberg MH. The molecular basis for platelet function. In Hematology. Basic Principles and Clinical Practice. 3rd Edn. ed. Hoffman R, Benz Jr EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P. Churchill Livingstone; New York, New York: 2000: 1741-52.
• 61 Marcus AJ. Platelets and their disorders. In Disorders of Hemostasis. ed. Ratnoff OD, Forbes CD. 3rd Edn. W.B. Saunders; Philadelphia, PA: 1996: 79-137.
• 62 Packham MA, Rand ML, Kinlough-Rathbone RL. Aggregation. in Platelets in Thrombotic and Non-Thrombotic Disesase. Pathology, Pharmacology and Therapeutics. ed. Gresele P, Page C, Foster V, Vermylen J. Cambridge University Press; Cambridge, UK: 2002: 338-56.
• 63 Brass LF. The molecular basis for platelet activation. in Hematology. Basic Principles and Clinical Practice. 3rd Edn. ed. Hoffman R, Benz Jr EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P. Churchill Livingston; New York, New York: 2000: 1753-70.
• 64 Marcus AJ, Safier LB. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J 1993; 07: 16-522.
• 65 Hoylaerts MF, Oury C, Toth-Zamboki E. et al. ADP receptors platelet activation and aggregation. Platelets 2000; 11: 307-9.
• 66 Kroll MH, Sullivan R. Mechanisms of platelet activation. in Thrombosis and Hemostasis. 2nd Edn. ed. Loscalzo J, Shafer AJ. Williams and Wilkins; Baltimore, MD: 1998: 261-91.
• 67 Vu T-KH, Hung DT, Wheaton VI. et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
• 68 Rasmussen UB, Vouret-Craviari V, Jallat S. et al. Cloning and expression of a hamster α-thrombin receptor coupled to Ca²+ mobilization. FEBS Lett 1991; 288: 123-8.
• 69 Hung DT, Wong YH, Vu T-KH. et al. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate both phosphoinositide hydrolysis and inhibit adenyl cyclase. J Biol Chem 1992; 353: 20831-4.
• 70 Couglin SR. How thrombin ‘talks’ to cells Molecular mechanisms and roles in vivo. Arterioscler Thromb Vasc Biol 1998; 18: 514-8.
• 71 Kahn ML, Nakanishi-Matsui M, Shapiro MJ. et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-87.
• 72 Fukami MH, Holmsen H, Kowalska MA. et al. Platelet secretion. in Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 4th Edn. ed. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Lippincott, Williams and Wilkins; Philadelphia, PA: 2001: 561-73.
• 73 Heemskerk JWM, Siljander PRM, Bevers EM. et al. Receptors and signalling mechanisms in the procoagulant response of platelets. Platelets 2000; 11: 301-6.
• 74 Andersen H, Greenberg DL, Fujikawa K. et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Nat Acad Sci USA 1999; 96: 11189-93.
• 75 Hempker HC. Platelet procoagulant activities: the amplification loops between platelets and the plasmatic clotting system. in Platelets in Thrombotic and Non-Thrombotic Disease. Pathology, Pharmacology and Therapeutics. ed. Gresele P, Page C, Foster V, Vermylen J. Cambridge University Press; Cambridge, UK: 2002: 381-92.
• 76 Heemskerk JWM, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-93.
• 77 Ganguly P. Binding of thrombin to human platelets. Nature 1974; 247: 306-7.
• 78 Tollefsen DM, Feagler JR, Majerus PW. The binding of thrombin to the surface of human platelets. J Biol Chem 1974; 249: 2646-51.
• 79 Tollefsen DM. Majerus PW. Evidence for a single class of thrombin-bindning sites of human platelets. Biochemistry 1976; 15: 2144-9.
• 80 Martin BM, Wasiewski WW, Fenton JWII. et al. Equilibrium binding of thrombin to platelets. Biochemistry 1976; 15: 4886-93.
• 81 Workman Jr GF. White GC II, Lundblad RL. Structure Function Relationships in the Interaction of α-Thrombin with Blood Platelets. J Biol Chem 1977; 252: 7118-23.
• 82 White II GC, Workman Jr GF, Lundblad RL. The binding of Thrombin to Thrombasthenic Platelets. J Lab Clin Med 1978; 91: 76-82.
• 83 Okumura T, Hasitz M, Jamieson GA. Platelet glycocalicin. Interaction with thrombin and role as thrombin receptor. J Biol Chem 1978; 253: 3435-43.
• 84 Jamieson GA, Okumura T. Reduced thrombin binding and aggregation in Bernard-Soulier platelets. J Clin Invest 1978; 61: 861-4.
• 85 Jamieson GA, Jung SM, Ordinas A. Factors affecting the high-affinity binding of thrombin to platelets. Ann N Y Acad Sci 1981; 370: 96-100.
• 86 Harmon JT, Jamieson GA. Thrombin binds to a high-affinity approximately 900,000-dalton site on human platelets. Biochemistry 1985; 24: 58-64.
• 87 De Candia E, Hall SW, Rutella S. et al. Binding of Thrombin to Glycoprotein Ib Accelerates the Hydrolysis of Par-1 on Intact Platelets. J Biol Chem 2001; 276: 4692-8.
• 88 Mazzucatto M, De Marco L, Masoth A. et al. Characterization of the initial α-thrombin interaction with glycoprotein Ibα in relation to platelet activation. J Biol Chem 1998; 273: 1880-7.
• 89 Wu H-f, White II GC, Workman Jr EF. et al. Affinity Chromatography of Platelets on Immobilized Thrombin: Retention of Catalytic Activity by Platelet-Bound Thrombin. Thromb Res 1992; 67: 419-27.
• 90 Mosesson M. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89: 9-12.
• 91 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by antithrombin III: implications for heparin efficacy. Proc Nat Acad Sci USA 1989; 86: 3619-23.
• 92 Jenny NS, Mann KG. Coagulation cascade: An overview. in Thrombosis and Hemorrhage. 2nd Edn. ed. Loscalzo J, Schafer AI. Williams & Wilkins; Baltimore, MD: 1998: 3-27.
• 93 Colman RW, Clowes AW, George JN. et al. Overview of hemostasis, in Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 4th Edn. ed. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Lippinott Williams & Wilkins; Philadelphia, PA: 2001: 2-16.
• 94 Minnema MC, Ten Cate H, Hack CE. (1999), The role of factor XI in coagulation: a matter of revision. Semin Thromb Hemost 1999; 25: 419-28.
• 95 Baglia FA, Walsh PN. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. J Biol Chem 2000; 275: 20514-19.
• 96 Rapaport SI, Schiffman S, Patch MJ. et al. The importance of the activation of antihemophilic globulin and proaccerelin by traces of thrombin in the generation of intrinsic prothrombinase activity. Blood 1963; 21: 221-6.
• 97 Butenas S, van’t Veer C, Mann KG. “Normal” thrombin generation. Blood 1999; 94: 2169-78.
• 98 Nesheim JE, Mann KG. Thrombin-catalyzed activation of single-chain bovine factor V. J. Biol Chem 1979; 254: 1326-34.
• 99 Thompson AR. Structure and function of the factor VIII gene and protein. Sem Thromb Hemost 2003; 29: 11-22.
• 100 Pieters J, Lindhout T, Hempker HC. In situgenerated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74: 1021-4.
• 101 Hettasch JM, Greenberg CS. Fibrin formation and stabilization. in Thrombosis and Hemorrhage. 2nd Edn. ed. Loscalzo J, Schafer AI. Williams & Wilkins: Baltmore, MD; 1998: 129-54.
• 102 Hantgan RP, Simpson-Haidaris PS, Francis CW. et al. Fibrinogen structure and physiology. In Thrombosis and Hemostasis. Basic Principles and Clinical Practice. 4th Edn. eds. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Lippincott, Williams and Wilkins; Philadelphia, PA: 2001: 203-32.
• 103 Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 11-30.
• 104 Loewy AG, McDonagh JM, Mikkola H. et al. Structure and function of factor XIII. in Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 4th Edn. ed. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Lippincott, Williams and Wilkins; Philadelphia, PA: 1998: 233-47.
• 105 Lorand L. Factor XIII: Structure, activation and interactions with fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 291-311.
• 106 Siddelmann JJ, Gram J, Jesparson J. et al. Fibrin clot formation and lysis: Basic mechanisms. Sem Thromb Hemost 2000; 26: 605-18.
• 107 Gabriel DA, Smith LA, Folds JD. et al. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med 1983; 101: 545-52.
• 108 Bale MD, Mosher DF. Effects of thrombospondin on fibrin polymerization and structure. J Biol Chem 1986; 261: 862-8.
• 109 Wolberg AS, Gabriel DA, Hoffman M. Analyzing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis 2002; 13: 533-9.
• 110 Carr ME, Gabriel DA. The effect of dextran 70 on the structure of plasma-derived fibrin gels. J Lab Clin Med 1980; 96: 985-93.
• 111 Nair CH, Dhall DP. Studies on fibrin network structures: the effect of some plasma proteins. Thromb Res 1991; 61: 315-25.
• 112 Gabriel DA, Muga K, Boothroyd EM. (1992), The effect of fibrin structure on fibrinolysis. J Biol Chem. 1992 267. 24259-63.
• 113 Carr Jr ME, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coagul Fibrinolysis 1995; 06: 567-73.
• 114 Wu JH, Siddiqui K, Diamond SL. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis. Thromb Haemost 1994; 72: 105-12.
• 115 Meh DA, Mosesson MW, DiOrio JP. et al. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis. Blood Coagul Fibrinolysis 2001; 12: 627-37.
• 116 Reeder SB, Widlus DM, Lazinger M. Lowdose thrombin injection to treat iatrogenic femoral artery pseudoaneurysms. AJR 2001; 177: 595-8.
• 117 Mann KG, Elion J, Butkowski RJ. et al. Prothrombin. Methods Enzymol 1981; 80 Pt.C: 286-302.
• 118 Lundblad RL, Kingdon HS, Mann KG. Thrombin. Methods Enzymol 1976; 45: 156-76.
• 119 Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol 1992; 29: 213-26.
• 120 Tollersrud OK, Helgeland L. On the quantification of prothrombin from different species using Echis carinatus as activator. Thromb Res 1986; 42: 737-47.
• 121 Jenny R, Church W, Odegaard B. et al. Purification of six human vitamin K-dependent proteins in a single chromatographic step using immunoaffinity columns. Prep Biochem 1986; 16: 227-45.
• 122 Flengsrud R. Purification and some characteristics of the human coagulation factor VII. Eur J Biochem 1979; 98: 455-64.
• 123 Suomela H, Myllyla G, Raaska E. Preparation and properties of a therapeutic factor IX concentrate. Vox Sanguines 1977; 33: 37-50.
• 124 White 2nd GC, Lundblad RL, Kingdon HS. Prothrombin complex concentrates: preparation, properties, and clinical uses. Curr Top Hematol 1979; 02: 203-44.
• 125 Lawson JH, Kalafatis M, Stram S. et al. (1994), A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 23357-66.
• 126 Radcliffe RD, Barton PG. Comparisons of the molecular forms of activated bovine factor X. Properties of activation with Russell’s viper venom, insoluble trypsin, sodium citrate, tissue factor, and the intrinsic system. J Biol Chem 1973; 248: 6788-95.
• 127 Lundblad RL. A rapid method for the purification of bovine thrombin and inhibition of the purified enzyme with phenylmethylsulfonyl fluoride. Biochemistry 1971; 10: 2501-6.
• 128 Church FC, Winna HC. Rapid sulfopropyldisk chromatographic purification of bovine and human thrombin. Anal Biochem 1986; 157: 77-83.
• 129 Griffith MJ. Covalent modification of human alpha-thrombin with pyridoxal-5’-phosphate. Effect of phosphopyridoxylation on the interaction of thrombin with heparin. J Biol Chem 1979; 254: 3401-6.
• 130 DiBella EE, Maurer MC, Scheraga HA. Expression and folding of recombinant bovine prothrombin-2 and its activation to thrombin. J Biol Chem 1995; 270: 163-9.
• 131 Russo G, Gast A, Schlaeger E-J. et al. Stable expression and purification of a secreted human recombinant prethormbin-2 and its activation to thrombin. Protein Expr Purif 1997; 10: 214-25.
• 132 Côté HCF, Stevens WK, Bajzar L. et al. Characterization of a stable form of human meizothrombin derived from recombinant prothrombin (R155A, R271A, and R284A). J Biol Chem 1994; 269: 11374-80.
• 133 Soejima K, Mimura N, Yonemura H. et al. (2001), An efficient refolding method for the preparation of recombinant human prothrombin-2 and characterization of the recombinant-derived α-thrombin. J Biochem 2001; 130: 269-77.
• 134 ZymoGenetics delays studies on one drug; may begin another early, Puget Sound Business Journal. September 2002 http://www.bizjournals.com/seattle/stories/2002/09/16/daily/12.html
• 135 Price BD. General patient care and safety. in Surgical Technology for the Surgical Technologist: A positive care approach. ed Caruthers BL, Price P, Junge TL, Price BD. Delmer Thompson Learning; Albany, New York: 2001: 118-49.
• 136 Jackson MR. Topical Hemostatic Agents for Localized Bleeding. In Consultative Hemostasis and Thrombosis. ed. Kitchens CJ, Alvig BM, Kessler CM. W.B. Saunders Company; Philadelphia, PA: 2002: 419-24.
• 137 Frey KB. Orthopedic Surgery. in Surgical Technology for the Surgical Technologist: A positive care approach. ed Caruthers BL, Price P, Junge TL, Price BD. Delmer Thompson Learning; Albany, New York: 2001: 668-98.
• 138 Noel AA, Swan KG, Deitch EA. Hemostasis. in Tools of the Trade and Rules of the Road. A Surgical Guide. ed. Deitch EA. Lippincott-Raven: Philadelphia, PA; 1997: 74-84.
• 139 Raina S, Upperman JS, Deitch EA. Control of Hemorrhage. in Tools of the Trade and Rules of the Road. A Surgical Guide. ed. Deitch EA. Lippincott-Raven; Philadelphia, PA: 1997: 163-74.
• 140 Kansal N, Koneru B, Deitch EA. Dressings and Bandages. in Tools of the Trade and Rules of the Road. A Surgical Guide. ed. Deitch EA. Lippincott-Raven; Philadelphia, PA: 1997. pps.
• 141 Ofodile FA, Sadana MK. The role of topical thrombin in skin grafting. J Natl Med Assoc 1991; 83: 416-8.
• 142 Higuchi D, Sei Y, Suzuki T. et al. Management of wounds treated by thrombin coagulation. Burns Incl Therm Inj 1987; 13: 75-6.
• 143 Robertson RD, Bond P, Wallace B. et al. The tumescent technique to significantly reduce blood loss during burn surgery. Burns 2001; 27: 835-8.
• 144 Gomez M, Logsetty S, Fish JS. Reduced blood loss during burn surgery. J Burn Care Rehabil 2001; 22: 111-7.
• 145 Cartotto R, Musgrave MA, Beveridge M. et al. Minimizing blood loss during surgery. J Trauma 2000; 49: 1034-9.
• 146 Barret JP, Dziewulski P, Wolf SE. et al. Effect of topical and subcutaneous epinephrine in combination with topical thrombin in blood loss during immediate near-total burn wound excision in pediatric burned patients. Burns 1999; 25: 509-13.
• 147 Sawada Y, Yotsuyanagi T. A technique of haemostasis of the extremities after debridement of burn wounds. Burns 1992; 18: 412-5.
• 148 Sawada Y, Ara M, Yotsuyanagi T. A thrombin ointment that achieves rapid haemostasis of split thickness donor wounds, particularly on the scalp. Burns 1991; 17: 225-7.
• 149 Brezel BS, McGeever KE, Stein JM. Epinephrine v thrombin for split-thickness donor site hemostasis. J Burn Care Rehabil 1987; 08: 132-4.
• 150 Prasad JK, Taddonio FE, Thomson PD. Prospective comparison of a bovine collagen dressing to bovine spray thrombin for control of haemorrhage of skin graft donor sites. Burns 1991; 17: 70-1.
• 151 Kudryashov BA. Use of the enzyme thrombin as a hemostatic during the World War II. Biokhimia 1975; 40: 452-5.
• 152 Gamba G, Fornasari PM, Grignani G. et al. Haemostasis during transvesical prostatic adenomectomy. A controlled trial on the effects of drugs with antifibrinolytic and thrombin-like activities. Blut 1979; 39: 89-98.
• 153 Sanfilippo JS, Barrows GH, Yussman MA. Comparison of avitene, topical thrombin, and gelfoam as sole hemostatic agent in turboplasties. Fertil Steril 1980; 33: 311-6.
• 154 Vaziri ND, Robinson MA, Barton C. et al. Control of bleeding from cannulation sites with topical thrombin in dialyzed patients. J Dialysis 1978; 02: 393-8.
• 155 Jasani B, Baxter-Smith DC, Donaldson LJ. et al. Topical thrombin and control of wound haematoma. Lancet 1977; 02 8033 332-3.
• 156 Rengachary SS, Manguoglu AB. Control of bone bleeding during Cloward procedure. Technical Note. J Neurosurg 1980; 52: 138-9.
• 157 Vaziri ND. Topical thrombin and control of bleeding from the fistula puncture sites in dialyzed patients. Nephron 1979; 24: 254-6.
• 158 Guimarães CA. (2002), Massive Hemoptysis. in Thoracic Surgery. 2nd Edn. ed. Pearson FGJD, Cooper J, Deslauriers RJ. et al. Churchill Livingstone; New York, New York: 2002: 717-36.
• 159 Moore WS. Vascular Surgery. A comprehensive review. 6th edn. W.B. Saunders Company; Philadelphia, PA: 2002: 689-90.
• 160 Morgan R, Belli A-M. Current treatment methods of Postcatheterization pseudoaneurysm. J Vasc Interv Radiol 2003; 14: 697-710.
• 161 Katzenschlager R, Ugurluoglu A, Ahmadi AS. et al. (1995), Incidence of pseudoaneurysm after diagnostic and therapeutic angiography. Radiology 1995; 195: 463-6.
• 162 Self SB. Cardiopulmonary consult. Thrombin injection for pseudoaneurysm. http://www.jewishheartlung.org/education/cardiopulmonary/thrombin.html .
• 163 Kruger K, Zahringer M, Sohngen FD. et al. Femoral pseudoaneurysms: management with percutaneous thrombin injections – success rate and effects on systemic coagulation. Radiology 2003; 226: 452-8.
• 164 Teh LG, Sieunarine K. Thrombin injection for repair of pseudoaneurysms: a case for caution. Australas Radiol 2003; 47: 64-6.
• 165 Xue M, Del Bigio MR. Acute tissue damage after injection of thrombin and plasmin into rat striatum. Stroke 2001; 32: 2164-9.
• 166 Xi G, Reiser G, Keep RF. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?. J Neurochem 2003; 84: 3-9.
• 167 Akassoglou K, Akpinar P, Murray S. et al. (2003), Fibrin is a regulator of Schwann cell migration after sciatic nerve injury in mice. Neurosci Lett 2003; 338: 185-8.
• 168 Olsen DM, Rodriguez JA, Vranic M. et al. A prospective study of ultrasound scan-guided thrombin injection of femoral pseudoaneurysm: A trend toward minimal medication. J Vasc Surg 2002; 36: 779-82.
• 169 Carrasco H, Parry CF. Transcatheter embolization of abdominal artery aneurysms. AJR 1982; 138: 729-33.
• 170 McLean GK, Stein EJ, Burke DR. et al. Steel occlusion coils: Pretreatment with thrombin. Radiology 1986; 158: 549-50.
• 171 Schwartz LB, Clark ET, Gewerts BL. Anastomotic and other pseudoaneurysms. in Vascular Surgery. 6th Edn. ed. Rutherford RB. W.B. Saunders Company; Philadelphia, PA: 2000: 752-63.
• 172 Ansell JE, Wildrich WC, Johnson WC. et al. Gelfoam and Autologous Clot Embolization: Effect on Coagulation. Invest Radiol 1978; 13: 115-20.
• 173 Gianturco C, Anderson JH, Wallace S. Mechanical devices for arterial occlusion. AJR 1975; 124: 428-35.
• 174 Goldman ML, Freeny PC, Tallman JM. et al. Transcatheter vascular occlusion therapy with isobutyl-2-cyanoacrylate (Bucrylate®) for control of massive upper gastrointestinal bleeding. Radiology 1978; 129: 41-9.
• 175 Goldman ML, Serrafizadeh MS, Philip PK. et al. Bucrylate embolization of abdominal aortic aneurysms: An adjunct to nonresective therapy. AJR 1980; 135: 1195-200.
• 176 Cope C, Zeit R. Coagulation of aneurysms by percutaneous thrombin injection. AJR 1986; 147: 383-7.
• 177 Berguer R, Schneider J, Wilner HI. Induced thrombosis of inoperable abdominal aortic aneurysm. Surgery 1978; 84: 425-9.
• 178 Reuter SP, Carlson SN. Thrombosis of a common iliac artery aneurysm by selective embolization and extraanatomic bypass. AJR 1980; 134: 1248-50.
• 179 Rogoff PA, Stock JO. Percutaneous transabdominal embolization of an iliac artery aneurysm. AJR 1985; 145: 1258-60.
• 180 Schwartz SI. Hemostasis, Surgical Bleeding, and Transfusion, Chapter 3. In Principles of Surgery. 4th Edn. ed. Schwartz SI, Shires GT, Spencer FC, Stover E.D.. McGraw-Hill; New York, New York: 1984: 100-47.
• 181 Kang SS, Labropoulos N, Mansour A. et al. Percutaneous ultrasound guided thrombin injection: A new method for treating postcatheterization femoral pseudoaneurysms. J Vasc Surg 1998; 27: 1032-8.
• 182 Kang SS, Labropoulos N. Nonoperative treatment of femoral pseudoaneurysms. in Practical Vascular Surgery. ed. Yao JST, Pearce WH. Appleton & Lange; Stamford, CT: 1999: 353-61.
• 183 Ferguson JD, Whatling PJ, Martin V. et al. Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention. Heart 2001; 85: E5
• 184 Pezzolo JA, Dupuy DE, Cronin JJ. Percutaneous injection of thrombin for the treatment of pseudoaneurysms after catheterization: An alternative to sonographically guided compression. AJR 2000; 175: 1035-40.
• 185 Maleux G, Hendricks S, Vaninbroudx J. et al. Percutaneous injection of human thrombin to treat iatrogenic femoral aneurysms: short-and midterm ultrasound follow-up. Eur Radiol 2003; 13: 209-12.
• 186 Lian C-S, Ho F-M, Chen M-F. et al. Treatment of iatrogenic femoral artery pseudoaneurysm with percutaneous thrombin injection. J Vasc Surg 1997; 26: 18-23.
• 187 Sackett WR, Taylor SM, Coffey CB. et al. Ultrasound-guided thrombin injection of iatrogenic femoral pseudoanerysms: a prospective analysis. Am Surg 2000; 66: 937-40.
• 188 McCoy D, Sharfstein B, Walker W. et al. Ultrasound-guided percutaneous thrombin injection for femoral artery. Am Surg 2000; 66: 975-7.
• 189 Morrison SL, Obrand DA, Steinmetz OR. et al. Treatment of femoral artery pseudoaneurysms with percutaneous thrombin injection. Ann Vasc Surg 2000; 14: 634-9.
• 190 Hughes MM, McCall JM, Nott DM. et al. Treatment of iatrogenic femoral artery pseudoaneurysms using ultrasound-guided injection of thrombin. Clin Radiol 2000; 55: 749-51.
• 191 Sheivman RG, Brophy DP. Treatment of iatrogenic femoral pseudoaneurysms with percutaneous thrombin injection: experience in 54 patients. Radiology 2001; 219: 123-7.
• 192 Calton Jr WC, Franklin DP, Elmore JR. et al. Ultrasound-guided thrombin injection is a safe and durable treatment for femoral pseudoaneurysms. Vasc Surg 2001; 35: 379-83.
• 193 Vermeulen EG, Umans U, Rijbroek A. et al. Percutaneous duplex-guided thrombin injection for treatment of iatrogenic femoral artery pseudoaneurysms. Eur J Vasc Endovasc Surg 2000; 20: 302-4.
• 194 Tamin WZ, Arbid EJ, Andrews LS. et al. Percutaneous induced thrombosis of iatrogenic femoral pseudoaneurysms following catheterization. Ann Vasc Surg 2000; 14: 254-9.
• 195 Reeder SB, Widlus DM, Lazinger M. Lowdose thrombin injection to treat iatrogenic femoral artery pseudoaneurysms. AJR 2001; 177: 595-8.
• 196 Ferguson JD, Whatling PJ, Martin V. et al. (2001), Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention. Heart 2001; 85: E5.
• 197 Bloom AI, Sasson T, Verstandig A. et al. Ultrasound-guided thrombin injection for the treatment of iatrogenic pseudoaneurysm of the femoral artery. Isr Med Assoc J 2001; 03: 649-52.
• 198 Pezzullo JA, Dupuy DE, Cronan JJ. Percutaneous injection of thrombin for the treatment of pseudoaneurysms after catheterization: an alternative to sonographically guided compression. AJR 2000; 175: 1035-40.
• 199 Paulson EK, Sheafor DH, Kliewer MA. et al. Treatment of iatrogenic femoral arterial pseudoaneurysms: comparison of US-guided thrombin injection with compression repair. Radiology 2000; 215: 403-8.
• 200 Brophy DP, Sheiman RG, Amatulle P. et al. Iatrogenic femoral pseudoaneurysms: thrombin injection after failed US-guided compression. Radiology 2000; 214: 278-82.
• 201 Partap VA, Cassoff J. Ultrasound-guided percutaneous thrombin injection for treatment of femoral pseudoaneurysms: technical note. Can Assoc Radiol J 2000; 50: 182-4.
• 202 Owen RJ, Haslam PJ, Elliott ST. et al. Percutaneous ablation of peripheral pseudoaneurysms using thrombin: a simple and effective solution. Cardiovasc Intervent Radiol 2000; 23: 441-6.
• 203 Weinmann EE, Chayen D, Kobzantzev ZV. et al. (2002), Treatment of postcatheterization false aneurysms: ultrasound-guided compression vs ultrasound-guided thrombin injection. Eur J Vasc Surg 2002; 23: 68-72.
• 204 Paulson EK, Nelson RC, Mayes CE. et al. Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution. AJR 2001; 177: 309-16.
• 205 Olsen DM, Rodriguez JA, Vranic M. et al. A prospective study of ultrasound scan-guided thrombin injection of femoral pseudoaneurysm: A trend toward minimal medication. J Vasc Surg 2002; 36: 779-82.
• 206 Criado E. Regarding “Thrombin injection for failed stent graft repair of perforated atherosclerotic aortic ulcer”. J Vasc Surg 2003; 37: 222-3.
• 207 Sultan S, Nicholls S, Madhavan P. et al. Ultrasound guided human thrombin injection. A new modality in the management of femoral artery pseudo-aneurysms. Eur J Vasc Endovasc Surg 2001; 22: 542-5.
• 208 Quarmby JW, Engelke C, Chitolie A. et al. Autologous thrombin for treatment of pseudoaneurysms. Lancet 2002; 359: 946-7.
• 209 Elford J, Burell C, Freeman S. et al. Human thrombin injection for the percutaneous treatment of iatrogenic pseudoaneurysms. Cardiovasc Intervent Radiol 2002; 25: 115-8.
• 210 Engelke C, Quarmby U, Ubhayakar G. et al. Autologous thrombin: a new embolization treatment for traumatic intrasplenic pseudoaneurysm. J Endovasc Ther 2002; 09: 36-7.
• 211 Tisseel. http://www.baxter.ca/htdocs/en/doctors/biosurgery/products_tisseel.html .
• 212 www.kingpharma.com .
• 213 King Pharmaceuticals 2001 Annual Report. http://www.kingpharma.com/anual_report.asp
• 214 Ortel TL, Charles LA, Keller FG. et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 1994; 45: 128-35.
• 215 Ortel TL, Mercer MC, Thames EH. et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001; 233: 88-96.
• 216 Schoenecker JG, Hauck RK, Mercer MC. et al. Exposure to topical bovine thrombin during surgery elicits a response again the xenogenic carbohydrate galactose alpha-1-3-galactose. J Clin Immunol 2000; 20: 434-44.
• 217 Su Z, Izumi T, Thames EH. et al. Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med 2002; 139: 349-56.
• 218 Neschis DG, Heyman MR, Cheanvechai V. et al. Coagulopathy as a result of factor Vinhibitor after exposure to bovine topical thrombin. J Vasc Surg 2002; 35: 400-2.
• 219 Israels SJ, Israels ED. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am J Pediatr Hematol Oncol 1994; 16: 249-54.
• 220 Spero JA. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg 1993; 78: 817-20.
• 221 Rapaport SI, Zivelin A, Minow RA. et al. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992; 97: 84-91.
• 222 Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76: 2011-6.
• 223 Berruyer M, Amiral J, Ffrench P. et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg 1993; 105: 892-7.
• 224 Kajitani M, Ozdemir A, Aguinaga M. et al. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg 2000; 15: 378-82.
• 225 Muntean W, Zenz W, Edlinger G. et al. (1997), Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin. Thromb Haemost 1997; 77: 1223.
• 226 Cmolik BL, Spero JA, Magovern GJ. et al. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg 1993; 105: 222-7.
• 227 Flaherty MJ, Henderson R, Wener MH. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann Intern Med 1989; 111: 631-4.
• 228 Banninger H, Hardegger T, Tobler A. et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Brit J Haematol 1993; 85: 528-32.
• 229 Cruickshank MK, Black J, Wall W. Development of a factor V and thrombin inhibitor following partial hepatic resection and the use of topical thrombin concentrate. Clin Lab Hematol 1994; 16: 187-90.
• 230 Muntean W, Zenz W, Finding K. et al. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-yearold child. Acta Paediatr 1994; 83: 84-7.
• 231 Chouhan VD, De La Cadena RA, Nagaswami C. et al. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost 1997; 77: 343-9.
• 232 Dorion RP, Hamati HF, Landis B. et al. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 1998; 122: 887-94.
• 233 Christie RJ, Carrington L, Alving B. Postoperative bleeding induced by topical bovine thrombin: report of two cases. Surgery 1997; 121: 708-10.
• 234 Zumberg MS, Waples JM, Kao KJ. et al. Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant. Am J Hematol 2000; 64: 59-63.
• 235 Tarantino MD, Ross MP, Daniels TM. et al. (1997), Modulation of an acquired factor V inhibitor with intravenous immune globulin. J Pediatr Hematol Oncol 1997; 19: 226-31.
• 236 Nelson PA, Powers JN, Estridge TD. et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res 2001; 58: 710-9.
• 237 Gershon SK, Chang AC, Purvis WV. et al. Misadministration of Topical Bovine Thrombin. JAMA 1999; 282: 1919.
• 238 Schoenecker JG, Johnson RK, Lesher AP. et al. (2001), Exposure of mice to topical bovine thrombin induces systemic autoimmunity. Am J Pathol 2001; 159: 1957-69.
• 239 Zehnder JL, Leung LL. Immunological Consequences of Topical Bovine Thrombin. Am J Pathol 2001; 159: 2371.
• 240 Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002; 42: 18-26.
• 241 Michaud SE, Wang LZ, Korde N. et al. Purification of salmon thrombin and its potential as an alternative to mammalian thrombins in fibrin sealants. Thromb Res 2002; 107: 245-54.